Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Combination Chemotherapy
100%
Randomized Clinical Trial
100%
Cetuximab
100%
Motolimod
100%
Head-and-neck
100%
Squamous Cell Carcinoma of Head
100%
Hazard Ratio
66%
Placebo
44%
Overall Survival
44%
Injection Site Reaction
33%
Recurrent Metastatic
33%
Human Papillomavirus
33%
Metastatic Squamous Cell Carcinoma
33%
Toll-like
22%
Progression-free Survival
22%
Median Overall Survival
22%
Long Progression-free Survival
22%
Median Progression-free Survival
22%
Immune Response
11%
Pyrexia
11%
Anemia
11%
Adult Patients
11%
Increased Incidence
11%
Oral Cavity
11%
Randomized Placebo-controlled Trial
11%
Improved Outcomes
11%
Carboplatin
11%
Adaptive Immunity
11%
Patient Selection
11%
Subgroup Analysis
11%
Combination Treatment
11%
Significant Benefit
11%
Innate Immunity
11%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
11%
Oropharynx
11%
Response Evaluation Criteria in Solid Tumors (RECIST)
11%
Cisplatin
11%
Overall Safety
11%
Chemotherapy Cycles
11%
Intent-to-treat
11%
Survival Median
11%
Hypopharynx
11%
Fluorouracil
11%
Blinded Independent Central Review
11%
Acneiform Rash
11%
Well Tolerated
11%
Medicine and Dentistry
Squamous Cell Carcinoma
100%
Neck
100%
Combination Chemotherapy
100%
Cetuximab
100%
Motolimod
100%
Randomized Clinical Trials
100%
Hazard Ratio
66%
Progression Free Survival
66%
Overall Survival
66%
Placebo
55%
Wart Virus
33%
Injection Site Reaction
33%
Toll Like Receptor 8
22%
Biological Marker
11%
Innate Immunity
11%
Anemia
11%
Immunotherapy
11%
Oral Cavity
11%
Adaptive Immunity
11%
Carboplatin
11%
Intention-to-Treat Analysis
11%
Cisplatin
11%
Subgroup Analysis
11%
Exanthem
11%
Fluorouracil
11%
Oropharynx
11%
Controlled Clinical Trial
11%
Larynx
11%
Response Evaluation Criteria in Solid Tumors
11%
Chill
11%
Hypopharynx
11%
Oropharynx Carcinoma
11%
Chemotherapy
11%
Platinum
11%
Pharmacology, Toxicology and Pharmaceutical Science
Squamous Cell Carcinoma
100%
Randomized Clinical Trial
100%
Chemotherapy Regimens
100%
Cetuximab
100%
Motolimod
100%
Progression Free Survival
66%
Overall Survival
66%
Placebo
55%
Human Papillomavirus
33%
Injection Site Reaction
33%
Toll Like Receptor 8
22%
Anemia
11%
Biological Marker
11%
Solid Malignant Neoplasm
11%
Immunotherapy
11%
Cisplatin
11%
Carboplatin
11%
Rash
11%
Controlled Clinical Trial
11%
Fluorouracil
11%
Oropharynx Cancer
11%
Chill
11%
Oropharynx Carcinoma
11%
Platinum
11%